DHCR24 and metabolic dysfunction-associated steatotic liver disease: This study reports a novel strategy to activate liver X receptors (LXR) via pharmacological Δ24‐dehydrocholesterol reductase (DHCR24) inhibition for the treatment of NAFLD and potentially other cardiometabolic diseases.